Peptides in Netherlands
How peptides are regulated in Netherlands: the governing agency, how compounds are classified, and what import and possession look like in practice. Sourced to CBG-MEB (Medicines Evaluation Board) / IGJ (Health and Youth Care Inspectorate) and re-checked quarterly.
Netherlands regulates peptides primarily through its medicines framework, overseen by CBG-MEB (Medicines Evaluation Board) / IGJ (Health and Youth Care Inspectorate). The first question a regulator asks is whether a substance is a medicinal product; most peptides marketed for performance, recovery, or longevity fall under that framework rather than being treated as supplements.
Where a peptide is an authorised medicine it is typically prescription-only and supplied through pharmacies, and many are authorised EU-wide through the European Medicines Agency (EMA), valid across the EU and EEA. Where it is not authorised, it generally cannot be lawfully marketed for human use and tends to circulate as a "research chemical". That label does not confer legality for human consumption.
A peptide can also be an approved medicine in one country and have no authorisation in another (tesamorelin is the clearest example here, approved in the US but with no EU marketing authorisation). Importation and personal possession are handled separately from marketing authorisation, and the practical reality at customs can differ from the strict letter of the law.
This overview is not legal advice. For any specific compound, consult its country page below and verify the current position with CBG-MEB (Medicines Evaluation Board) / IGJ (Health and Youth Care Inspectorate).
Importation
In Netherlands, importing an unauthorised medicinal product, including for personal use, is restricted, and customs may detain shipments of unapproved substances. Any personal-use allowance is narrow and not guaranteed. Authorised medicines are intended to be supplied through regulated channels.
Personal possession
Personal possession of a lawfully prescribed medicine is ordinary in Netherlands. Possession of an unauthorised peptide is a grey area; enforcement generally focuses on sale and supply rather than individual possession, but this is not a guarantee and the position can change.
Penalties for sale
Selling or supplying unauthorised medicines, or supplying prescription-only medicines without authorisation, is an offence. CBG-MEB (Medicines Evaluation Board) / IGJ (Health and Youth Care Inspectorate) sets out the applicable sanctions; we deliberately do not reproduce specific figures here because they change. Confirm the current penalties with the regulator.